Cognetivity Neurosciences (CSE: CGN) appears to be on a roll when it comes to establishing pilot programs in new markets. Following the company entering a pilot program in Singapore earlier this month, the firm has now entered into a paid pilot program with a Japanese insurance giant.
The latest pilot program will be conducted with Mitsui Sumitomo Primary Life and Mitsui Sumitomo Aioi Life, which are both companies owned by MS&AD Insurance Group Holdings. MS&AD is viewed as a giant in the space, with over 13,000 employees and operations in fifty different countries and jurisdictions.
The program will see the firms OptiMind mobile app, which is based on the firms integrated cognitive assessment tech, deployed by MS&AD.
Sponsored · Selkirk Copper Mines
The purpose of the pilot program is to demonstrate the potential of the assessment tool for personal use, with the ultimate goal of deploying the tech at scale to the entire client base of MS&AD. Full deployment, of course, is contingent on the success of the pilot program.
The pilot program is being enacted through the venture arm of MS&AD, known as MS&AD Ventures, which provides support to the company and looks to discover advanced tech to add value to the model. The venture arm is set to confirm the utility of the app before deploying it through the Primary Life and Aioi Life subsidiaries.
“This is a very compelling deployment for us as it demonstrates that, through the use of our technology delivered on smartphones, users are able to measure their own brain function as part of their normal routine and adapt their lifestyle to maximize the performance of what is their most important organ and largest indicator of their overall health. Having more paid deployments in Asia adds to our growing commercial pipeline and provides strong additional validation of the global appeal of our technology,” commented CEO Sina Habibi.
Financial details of the pilot program were not provided, although the company did indicate it is a paid, pilot-based arrangement.
Cognetivity Neurosciences last traded at $0.335 on the CSE.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. We may buy or sell securities in the company at any time. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
